- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: $1 Alternative to Pricey Daraprim
What we're reading, December 1, 2015: $1 alternative to Daraprim being made available; over-the-counter medications are convenient and affordable but have their own dangers; and an analysis looks at the reasons why prescription drugs are so much more expensive in the US.
Express Scripts Will Sell $1 Daraprim Alternative
Following Turing Pharmaceuticals’ controversial decision to increase the price of the 62-year-old Daraprim to $750 a pill from $13.50 a pill, Express Scripts and Imprimis Pharmaceuticals will partner to increase access to a low-cost alternative of the drug. Daraprim is used to treat toxoplasmosis and the price increase puts it out of reach for people with HIV, pregnant women, and others with weakened immune systems. The compounded alternative will only cost $1 per capsule.
The Dangers of Over-the-Counter Medications
Over-the-counter medications used commonly to treat a variety of ailments are convenient and affordable, but are often used inappropriately. The New York Times reported that one-fifth of American adults admit to taking more than the recommended dose and using over-the-counter medications more frequently than they should. In addition, few consult a doctor or pharmacists first.
Behind the Higher Cost of Prescription Drugs in America
Although the cost of living in Norway is higher than the US, the price of prescription drugs is far higher in America, according to an analysis from The Wall Street Journal. Comparing drug prices paid for by Medicare Part B with those paid by Norway’s taxpayer-funded health system, the analysis revealed that 93% of 40 top branded drugs were more expensive in the US. The Journal found similar results when comparing the US to England and Canada’s Ontario province.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More
Health Equity & Access Weekly Roundup: April 14, 2025
April 14th 2025From the potential impact of tariffs to the World Health Organization's year-long campaign launch focused on improving maternal and newborn health and addressing preventable deaths, here's the latest from the Center on Health Equity & Access.
Read More
